Q & A with Dr. Peter Martin on High Dose Cytarabine for Mantle Cell Lymphoma Patients

In a recent interview with Clinical Advances in Hematology & Oncology, Dr. Peter Martin answered questions about the use of high dose cytarabine for patients with mantle cell lymphoma.

H&O How much does high-dose cytarabine improve patient outcome?

PM I do not think that has been very well defined. Not all of these data have sufficient long-term follow-up to comment on overall survival outcomes. Historically, patients were given R-CHOP followed by ASCT. The MCL-2 trial, published by Geisler and colleagues, added high-dose cytarabine and rituximab, and found that the outcomes were far superior in terms of progression-free survival and overall survival. However, these outcomes may not be solely due to high-dose cytarabine. Other explanations include the addition of rituximab, other changes in supportive care, and better pathology. Cytarabine may be part of that story, but it may not be the whole story.

The better trial to evaluate the potential role of cytarabine is the MCL Younger Trial that I mentioned earlier, which is a phase 3 trial published by Hermine and colleagues that compared 6 cycles of R-CHOP vs the R-CHOP/R-DHAP regimen. In this trial, the addition of R-DHAP seemed to reduce the risk of disease progression by approximately 30%. The study also found that the R-CHOP/R-DHAP regimen prepared people for ASCT better than R-CHOP alone.

A transcript of the full interview can be read here.



Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s